Concepedia

Drug Candidate Optimization

Drug Candidate Optimization is a systematic medicinal chemistry and pharmacokinetic refinement process that distinguishes itself by enhancing the metabolic stability, bioavailability, and safety profile of investigational compounds through iterative structural modification and in vitro microsomal stability assessment.

668

Publications

33.6K

Citations

6.6K

Authors

1.1K

Institutions

Publications per year

2017–2026

337

Parents

Publications

668

Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties

Travis T. Wager, Xinjun Hou, Patrick R. Verhoest et al. · ACS Chemical Neuroscience · 2010 · 1K citations

, , +17

Lipophilicity in drug discovery

Michael J. Waring · Expert Opinion on Drug Discovery · 2010 · 844 citations

, , +13

Rational Use of in Vitro P-glycoprotein Assays in Drug Discovery

Joseph W. Polli, Stephen A. Wring, Joan E. Humphreys et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 662 citations

, , +14

Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery

Travis T. Wager, Xinjun Hou, Patrick R. Verhoest et al. · ACS Chemical Neuroscience · 2016 · 605 citations · Full text

, , +11

Synthesis and Antibacterial Evaluation of Certain Quinolone Derivatives

Yeh‐Long Chen, Kuo‐Chang Fang, Shu‐Lin Hsu et al. · Journal of Medicinal Chemistry · 2001 · 550 citations

, , +12

1–5 of 668

Authors

6.6K

  1. RR
    Ruth R. Wexler

    Bristol-Myers Squibb (United States), United States

    7 publications · 770 citations

    7

    h-index

  2. PC
    Pancras C. Wong

    Bristol-Myers Squibb (United States), United States

    6 publications · 745 citations

    6

    h-index

  3. JM
    Joseph M. Luettgen

    Bristol-Myers Squibb (United States), United States

    6 publications · 745 citations

    6

    h-index

  4. KA
    Karen A. Rossi

    Bristol-Myers Squibb (United States), United States

    5 publications · 570 citations

    5

    h-index

  5. RM
    Robert M. Knabb

    Bristol-Myers Squibb (United States), United States

    4 publications · 680 citations

    4

    h-index

1–5 of 6.6K

Institutions

1.1K

  1. Pfizer (United States)

    New York, United States

    22 h-index

    378 publications

    31.9K citations

  2. Bristol-Myers Squibb (United States)

    New York, United States

    15 h-index

    198 publications

    15.5K citations

  3. Chinese Academy of Sciences

    Beijing, China

    15 h-index

    86 publications

    3.1K citations

  4. AstraZeneca (United Kingdom)

    Cambridge, United Kingdom

    13 h-index

    127 publications

    7.2K citations

  5. China Pharmaceutical University

    Nanjing, China

    11 h-index

    82 publications

    2.4K citations

  6. Amgen (United States)

    Thousand Oaks, United States

    11 h-index

    125 publications

    5.3K citations

  7. Merck & Co., Inc., Rahway, NJ, USA (United States)

    Rahway, United States

    10 h-index

    187 publications

    7.3K citations

  8. AstraZeneca (Sweden)

    Södertälje, Sweden

    10 h-index

    103 publications

    6.3K citations

1–8 of 1.1K

Venues

  1. Journal of Medicinal Chemistry

    180 publications · 10.8K citations

    61

    h-index

  2. ACS Medicinal Chemistry Letters

    27 publications · 1.3K citations

    19

    h-index

  3. Bioorganic & Medicinal Chemistry Letters

    16 publications · 317 citations

    12

    h-index

  4. Organic Process Research & Development

    15 publications · 400 citations

    12

    h-index

  5. ChemMedChem

    12 publications · 359 citations

    11

    h-index

1–5